ey0021.5-8 | Novel Treatments | ESPEYB21
Vanderniet Joel A.
, Szymczuk Vivian
, Hogler Wolfgang
, Beck-Nielsen Signe S.
, Uday Suma
, Merchant Nadia
, Crane Janet L.
, Ward Leanne M.
, Boyce Alison M.
, Munns Craig F.
In brief: This article reviews the evidence and provides expert opinion on the safe and appropriate use of denosumab in children and adolescents with RANKL-mediated disorders such as giant cell bone tumours, fibrous dysplasia and juvenile Pagets disease.Commentary: Receptor activator of nuclear factor κB ligand (RANKL) is expressed by osteogenic cells and induces osteoclast differentiation by binding to RANK on osteoclast precursors. Excessive...